Haematological malignancies (blood cancers)

CRISPR-Armed Phages Clear First Human Safety Bar
CMN Interview

Mar. 3, 2026

With phase 1 data published today in The Lancet Microbe, SNIPR is positioning its experimental CRISPR–Cas-armed phage cocktail, SNIPR001, not simply...

First cancer patient dosed in CRISPR-armed phage...
CMN Special

Jun. 12, 2025

SNIPR Biome has dosed the first patient in its Phase 1b trial of SNIPR001, a CRISPR-CAS-armed bacteriophage therapy that represents a new frontier in...

Haematological malignancies (blood cancers)

Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541444)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Pediatric Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541405)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Acute Myeloid Leukaemia, AML, (NCT07026942)
Sponsors:
Nationwide Children's Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or refractory B-cell non-Hodgkin's lymphoma, (NCT06838832)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, (NCT06514794)
Sponsors:
Wugen, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or refractory B-cell hematological malignancies, (NCT05381181)
Sponsors:
Bioray Laboratories
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed/​Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma, (NCT06934382)
Sponsors:
Stephan Grupp MD PhD, Children's Hospital of Philadelphia
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-cell Non-Hodgkin Lymphoma, NHL, (NCT06321289)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine